Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aminoglutethimide
Drug ID BADD_D00107
Description An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Indications and Usage For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.
Marketing Status Discontinued
ATC Code L02BG01
DrugBank ID DB00357
KEGG ID D00574
MeSH ID D000616
PubChem ID 2145
TTD Drug ID D0M6DO
NDC Product Code Not Available
Synonyms Aminoglutethimide | Cytadren | Orimeten
Chemical Information
Molecular Formula C13H16N2O2
CAS Registry Number 125-84-8
SMILES CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acid base balance abnormal13.02.01.001--Not Available
Adrenal insufficiency05.01.02.001; 14.11.01.004--
Agranulocytosis01.02.03.001--Not Available
Alveolitis allergic10.01.03.008; 22.01.01.002--Not Available
Anaemia01.03.02.001--
Arrhythmia02.03.02.001--Not Available
Atrial fibrillation02.03.03.002--
Atrial flutter02.03.03.003--
Atrial tachycardia02.03.03.004--
Body temperature increased13.15.01.001--Not Available
Coordination abnormal17.02.02.004--Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Disorientation17.02.05.015; 19.13.01.002--Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dyskinesia17.01.02.006--
Gait disturbance08.01.02.002; 17.02.05.016--
Goitre05.02.01.001; 14.11.01.008--Not Available
Haematemesis07.12.02.002; 24.07.02.011--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatotoxicity09.01.07.009; 12.03.01.008--Not Available
Hirsutism05.05.01.005; 23.02.04.001--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hypersensitivity10.01.03.003--
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene